AMX0035 in Adult Patients With Wolfram Syndrome
NCT05676034 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2026-04-14
Summary
This study is an open label Phase II study to evaluate the safety and efficacy of AMX0035 in adults with Wolfram syndrome.
Conditions
- Wolfram Syndrome
Interventions
- DRUG
-
AMX0035
AMX0035
Sponsors & Collaborators
-
Amylyx Pharmaceuticals Inc.
lead INDUSTRY
Principal Investigators
-
Camille Bedrosian, MD · Amylyx Pharmaceuticals
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-03-03
- Primary Completion
- 2024-07-23
- Completion
- 2028-05-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome
NCT03569631 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of RO4917523 in Patients With Fragile X Syndrome
NCT01517698 ·Status: COMPLETED ·Phase: PHASE2
-
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
NCT07209462 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of VRG50635 in Healthy Volunteers
NCT06286475 ·Status: COMPLETED ·Phase: PHASE1
-
Study of SPG601 in Adult Men With Fragile X Syndrome
NCT06413537 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome
NCT01325740 ·Status: SUSPENDED ·Phase: PHASE2
-
A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)
NCT03694275 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome
NCT01750957 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome
NCT01357239 ·Status: COMPLETED ·Phase: PHASE2
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
NCT05104983 ·Status: RECRUITING ·Phase: PHASE2
-
Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
NCT02324049 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
NCT06617429 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)
NCT05200104 ·Status: WITHDRAWN ·Phase: PHASE2
-
Effects of CX516 on Functioning in Fragile X Syndrome and Autism
NCT00054730 ·Status: COMPLETED ·Phase: PHASE2
-
The Natural History Study of Patients With Sanfilippo Disease(s) (MPS3)
NCT05705674 ·Status: RECRUITING
-
Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM
NCT00490789 ·Status: UNKNOWN ·Phase: PHASE2
-
Randomized Controlled Study of Donepezil in Fragile X Syndrome
NCT01120626 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome
NCT03047980 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A
NCT03023540 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome
NCT05812781 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease
NCT01463215 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2
-
Tracking Neurodegeneration in Early Wolfram Syndrome
NCT02455414 ·Status: COMPLETED
-
A Study With RO4917523 in Patients With Fragile X Syndrome
NCT01015430 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge
NCT05418049 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Synthetic Human Secretin in Children With Autism
NCT00036244 ·Status: COMPLETED ·Phase: PHASE3